anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Nebivolol
Trial phase: Not Applicable
ATC code: C07AB12 | C07BB12 | C07FB12 | C09DX05
SMILES: OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 54
Group description: nebivolol 2.5mg daily

Nebivolol: Nebivolol 25mg daily
Eligibility criteria:
Inclusion Criteria:

Males or females aged 18 or above
Blood pressure that meets any of the three following criteria:
BP should be <140/85 mmHg on a maximum of two anti-hypertensive drugs

Exclusion Criteria:

contraindications to beta-blockade
contraindications to thiazide use
if there was a history of asthma, diabetes, heart failure, bradycardia, atrial fibrillation, AV conduction disturbances
concurrent treatment with verapamil & dilitiazem
childbearing women
compelling indication for treatment with a beta blocker
any condition that will interfere with the treatment or the patient's ability to complete the study
Intervention: Vorinostat
Trial phase: Phase 1
ATC code: L01XH01
SMILES: O=C(CCCCCCC(=O)Nc1ccccc1)NO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: During Cycle 1, participants received a single oral dose of vorinostat 400 mg on Day 1 (fasted), Day 3 (fed), Day 19 (fed). On Days 5-18, participants received a single oral dose of vorinostat 400 mg once-daily in the morning. If participants did not match to the discontinuation criteria, they could continue the same dose level therapy during Cycle 2 and subsequent cycles. (Each cycle was 26 days.)
Eligibility criteria:
Inclusion Criteria:

Participants with histologically or cytologically diagnosed solid tumor; no standard therapy available or participant has failed to respond to standard therapy

Exclusion Criteria:

Participants with history of immunotherapy, radiotherapy, surgery, or chemotherapy during the previous 4 weeks; previous treatment is 5 or more chemotherapeutic regimens.
Any uncontrolled concomitant illness
Are pregnant or breast-feeding
Serious drug or food allergy
Intervention: Dalfampridine
Trial phase: Phase 3
ATC code: N07XX07
SMILES: Nc1ccncc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 228
Group description: 10 milligram (mg) tablet twice a day (b.i.d.)
Eligibility criteria:
Inclusion Criteria:

Have a confirmed diagnosis of multiple sclerosis
Are able to walk with or without an assistive device

Exclusion Criteria:

Pregnancy, breastfeeding or females of childbearing potential not using adequate birth control
Participating in other investigational drug trials
A medical history or clinical findings that preclude entry into the study
A medication history that precludes entry into the study
Previously treated with 4-aminopyridine (4-AP)
Intervention: Isoniazid
Trial phase: Phase 3
ATC code: J04AC01 | J04AC51 | J04AM01 | J04AM02 | J04AM03 | J04AM04 | J04AM05 | J04AM06 | J04AM07 | J04AM08
SMILES: NNC(=O)c1ccncc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 184
Group description: isoniazid (INH) (900 mg orally) given twice weekly for 9 months
Eligibility criteria:
Inclusion Criteria:

The inclusion criteria for this study will be San Francisco Jail inmates, age 18 or older (the jail does not house juveniles) having evidence of M. tuberculosis infection by positive tuberculin skin test (a documented reactive tuberculin skin test to 0.1 mL containing 5 Tuberculin Units) who meet current national criteria for therapy for tuberculosis infection and can provide informed consent.

Exclusion Criteria:

Ineligible for either therapy regimen for any of the following reasons:

history of treatment-limiting reaction to isoniazid or rifamycins;
pregnancy or breast feeding;
active tuberculosis;
an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper limit of normal;
bilirubin >2 times the upper limit of normal;
platelets <150 K/mm3;
taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs);
Unable to communicate in English or Spanish;
Unable or unwilling to provide informed consent;
Not in the routine level of jail security for any reason (housed in "special security" areas);
Any condition that, in the best judgment of the investigator, would pose a risk to the subject during the study.
Intervention: Bupropion
Trial phase: Phase 1 | Phase 2
ATC code: A08AA62 | N06AX12
SMILES: CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).

Bupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
Eligibility criteria:
Inclusion Criteria:

Ages 18 and older
Willingness and ability to give written consent
Smoking at least 10 cigarettes per day for at least 1 year
Baseline expired carbon-monoxide level of at least 10 ppm
Weigh at least 100 lbs.
English-speaking
One person per household
At least 1 prior quit attempt
Concern about gaining weight. This will be assessed using a questionnaire that will provide a rating system to determine qualified participants.

Exclusion Criteria:

Pregnant or nursing women or women attempting to conceive
Serious current neurologic, psychiatric or medical illness, including unstable cardiac, hepatic, or renal disease and diabetes and hypertension
Current alcohol dependence
Current use of opiates, and/or a urine toxicology screen positive for opiates
Chronic pain conditions necessitating opioid treatment (naltrexone, an opioid antagonist will make these medications ineffective)
Evidence of significant hepatocellular injury as evidenced by AST or ALT >3 x normal or elevated bilirubin
History of cirrhosis
Body mass index (BMI) greater than 35
History of anorexia nervosa or bulimia
Current major depression
Currently taking Toprol-XL (or metoprolol succinate)
History of seizure disorder or serious brain injury
Current use of smokeless tobacco, pipes, cigars, nicotine gum, nicotine patch, nicotine inhaler, nicotine lozenge, nicotine nasal spray, or bupropion
Previous hypersensitivity to bupropion
Patients requiring concomitant therapy with any psychotropic drug
Participation in the Framing Messages for Smoking Cessation With Bupropion study (HIC#: 10880)
Intervention: Clopidogrel
Trial phase: Phase 4
ATC code: B01AC04
SMILES: [H][C@@](C(=O)OC)(c1ccccc1Cl)N1CCc2sccc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 225
Group description: clopidogrel 75mg per day and matching placebo of cilostazol
Eligibility criteria:
Inclusion Criteria:

Cerebral infarction within 2 weeks from the onset or TIA with corresponding acute ischemic brain lesions on MRI within 2 weeks from the onset
Age: more than 35 years of age
Patient with significant focal stenosis in the M1 segment of middle cerebral artery (MCA) or basilar artery (BA) with acute ischemic lesions on magnetic resonance imaging (MRI) within the vascular territory of the stenosed artery.

Exclusion Criteria:

Patients with any contraindications to the treatment with antiplatelet therapy
Patients with potential cardiac embolic source; prosthetic valve, atrial fibrillation, atrial flutter, left atrial/atrial appendage thrombus, sick sinus syndrome, left ventricular thrombus, dilated cardiomyopathy, akinetic or hypokinetic left ventricular segment, atrial myxoma, Infective endocarditis, mitral valve stenosis or prolapse, mitral annuls calcification, left atrial turbulence, nonbacterial endocarditis, congestive heart failure, recent myocardial infarction (within 4 weeks)
Patients with more than 50% stenosis in the parent artery of symptomatic stenosis
Bleeding diathesis
Chronic liver disease (ALT > 100 or AST > 100) or chronic renal disease (creatinine > 3.0mg/dl)
Anemia (hemoglobin < 10mg/dl) or thrombocytopenia (platelet count less than 100,000/mm3)
Nonatherosclerotic vasculopathy; patients with clinical characteristics suggesting arterial dissection, moyamoya disease, Takayasu's arteritis, radiation associated angiopathy, and other vasculitis.
Severe stroke: NIH stroke scale : more than 16
Pregnant or lactating patients
Chronic user of NSAIDs
Thrombolytic therapy for the symptomatic stenosis
Symptomatic stenosis scheduled for angioplasty
Patients with pacemaker or any other contraindications to MRI
Intervention: Forteo
Trial phase: Phase 4
ATC code: H05AA02
SMILES: CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(N)CO)C(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(Cc1c[nH]cn1)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(Cc1c[nH]cn1)C(=O)NC(CC(C)C)C(=O)NC(CC(N)=O)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)NC(Cc1c[nH]cn1)C(=O)NC(CC(N)=O)C(=O)NC(Cc1ccccc1)C(=O)O)C(C)C)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 79
Group description: Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months

Teriparatide (FORTEO): Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
Eligibility criteria:
Inclusion Criteria:

Previous established diagnosis of Osteogenesis Imperfecta AND
> 2 previous adult fractures, AND/OR
BMD at lumbar spine, femoral neck or total hip T score < -2.0

Exclusion Criteria:

Open epiphyses.
History of external beam radiation to the skeleton.
Pagets disease.
Bone metastases or skeletal malignancies.
Total lifetime exposure to any antiresorptive medication < 90 days (Primary Inclusion).
Treatment with any antiresorptive medication 12 months proceeding enrollment - (Secondary Inclusion).
Women with OI who are pregnant or unwilling to use 1 form of contraception.
Vitamin D insufficiency (25-hydroxyvitamin D <15ng/ml)
Intervention: GLUTAMINE
Trial phase: Phase 2
ATC code: A16AA03
SMILES: NC(=O)CCC(N)C(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Glutamine dosage of 0.60 gm/kg body weight per day divided into two doses.
Eligibility criteria:
Inclusion Criteria:

Active patient (presently receiving medical care for SCA) at the St. Jude Comprehensive Sickle Cell Center (SJCSCC) or an affiliate or alliance of St Jude. Patient must not be in the high risk category as defined by the SJCSCC. High risk is defined as follows:

3 or more admissions and/or emergency department visits for pain within the past 12 months, or;
2 or more episodes of acute chest syndrome within the past 24 months, or;
A combination of pain and ACS events > 3 within the past 12 months.
5-18 years of age
Diagnosis of Hb SS or HB0Thal
Weight >15 kg
<50th percentile for height/age or weight/age or weight/ height, or <90% ideal body weight, or <90% of BMI for age/ gender.
Is willing to sign informed consent

Exclusion Criteria

Patients receiving hydroxyurea or any other anti-sickling agent, chronic transfusion, or nutrition supplements.A nutrition supplement is any high calorie or high protein food additive or oral supplement being used for the purpose of weight gain.
History of poor compliance (Missing two or more clinic appointments in the past year).
Renal or liver dysfunction
Renal dysfunction as defined by serum creatinine >1.5 times normal for age based on testing lab.
Hepatic dysfunction as defined by alanine aminotransferase (ALT) >2 times the upper limit of normal for age based on testing lab.
Breastfeeding
Pregnancy.Females of childbearing potential must have negative serum or urine pregnancy test (record date of test).
Patients enrolled on previous glutamine protocol (SCDGLU).
Patients who are considered high risk
Intervention: Glimepiride
Trial phase: Phase 3
ATC code: A10BB12 | A10BD04 | A10BD06
SMILES: CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 136
Group description: Avandia™ + Amaryl™ Arm: at month 2 initial dose of 4 mg +1 mg OD was titrated up to 8 mg + 1 mg OD; at month 4 it was further titrated up to 8 mg / 2 mg OD. At month 6, patients not achieving target received additional specified drug therapy: Metformin was added and titrated up to 1000 mg BID maximum dose for an additional 6 months.
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes patients
18 - 75 years old
Type 2 diabetes mellitus (DM) drug naïve or on submaximal oral monotherapy < 3 years

A1C criteria at screening:

7.1-10% for drug naïve patients after failure of diet control and life-style modification
7.1 - 9% on single therapy (e.g. not more 10 mg of Glyburide or 4 mg of Amaryl™ or 1000mg of Metformin) who will start after 2 weeks wash-out. During wash out the following will be done: i) diet and life style modification ii) Angiotensin converting enzyme inhibitor (ACE), aspirin (80 mg), and statin if appropriate
Signed informed consent

Exclusion Criteria:

Type 1 diabetes
Subjects currently treated with insulin
Subject treated for previous 3 month with any thiazolidinedione (TZD)
Evidence of clinically significant concomitant illnesses which are not controlled by medication and/or may limit participation in the study as judged by the investigator
Subjects who have hypersensitivity to any components of study drugs
Participation in a clinical trial and/or intake of an investigational drug within 30 days prior to screening.
Pregnant or nursing females
Females of childbearing potential who are not on adequate birth control
Liver enzymes (Alanine Aminotransferase (ALT) > 2.5 times upper limit of normal)
Renal impairment: serum creatinine ≥ 136umol/L (males) and ≥ 124 umol/L (females)
Congestive Heart Failure (CHF class III/IV)
Weight >160 kg
Intervention: Rosiglitazone
Trial phase: Phase 3
ATC code: A10BD03 | A10BD04 | A10BG02
SMILES: CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 117
Group description: Avandamet™ Arm: at month 2 the initial dose of 2 mg / 500 mg BID was titrated up to 4 mg / 500 mg BID; at month 4 it was be further titrated up to 4 mg / 1000 mg BID. At month 6, patients not achieving target received additional specified drug therapy Amaryl™ was added and titrated up to 4 mg OD maximum dose for an additional 6 months
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes patients
18 - 75 years old
Type 2 diabetes mellitus (DM) drug naïve or on submaximal oral monotherapy < 3 years

A1C criteria at screening:

7.1-10% for drug naïve patients after failure of diet control and life-style modification
7.1 - 9% on single therapy (e.g. not more 10 mg of Glyburide or 4 mg of Amaryl™ or 1000mg of Metformin) who will start after 2 weeks wash-out. During wash out the following will be done: i) diet and life style modification ii) Angiotensin converting enzyme inhibitor (ACE), aspirin (80 mg), and statin if appropriate
Signed informed consent

Exclusion Criteria:

Type 1 diabetes
Subjects currently treated with insulin
Subject treated for previous 3 month with any thiazolidinedione (TZD)
Evidence of clinically significant concomitant illnesses which are not controlled by medication and/or may limit participation in the study as judged by the investigator
Subjects who have hypersensitivity to any components of study drugs
Participation in a clinical trial and/or intake of an investigational drug within 30 days prior to screening.
Pregnant or nursing females
Females of childbearing potential who are not on adequate birth control
Liver enzymes (Alanine Aminotransferase (ALT) > 2.5 times upper limit of normal)
Renal impairment: serum creatinine ≥ 136umol/L (males) and ≥ 124 umol/L (females)
Congestive Heart Failure (CHF class III/IV)
Weight >160 kg
Intervention: MK-0873
Trial phase: Phase 2
SMILES: O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: Participants receive MK-0873 1.25 mg twice daily for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Rheumatoid arthritis, according to the American College of Rheumatology criteria, with active disease despite current medications
Other criteria also apply

Exclusion Criteria:

Other major illnesses
Past history of certain other disorders
Certain prohibited medications
Intervention: Ruboxistaurin
Trial phase: Phase 3
SMILES: CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 149
Group description: 32 milligrams (mg) taken orally daily for up to 48 months
Eligibility criteria:
Inclusion Criteria:

Type 1 or 2 diabetes
18 years or older
Hemoglobin A1c (HbA1c) less than or equal to 11%
Mild to very severe non-proliferative diabetic retinopathy in the study eye
Clinically significant macular edema in the study eye not within 100 microns of center of macula

Exclusion Criteria:

Previous surgery or laser treatment (or need for laser treatment within 3 months) in the study eye
Glaucoma in the study eye
Unstable cardiovascular disease
Major surgery within past 3 months
Significantly impaired kidney or liver function, or malignancy requiring chemotherapy or radiation therapy.
Intervention: Cyclophosphamide
Trial phase: Phase 1 | Phase 2
ATC code: L01AA01
SMILES: O=P1(N(CCCl)CCCl)NCCCO1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: All participants received two days of rituximab, then four days of high-dose cyclophosphamide followed by filgrastim. Participants then received six doses of KGEL vaccine over 24 weeks interspersed with four additional doses of rituximab.

KGEL vaccine: Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10^8 cells per dose. The first dose was given on Day +1.

Filgrastim: 5 mcg/kg/day starting on Day +6 until ANC is >= 1000/mcL.

Rituximab: 375 mg/m^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.

Cyclophosphamide: 50 mg/kg/day on Day -3, -2, -1, and 0.
Eligibility criteria:
DISEASE CHARACTERISTICS:

Histologically confirmed classical Hodgkin's lymphoma

Relapsed disease with achievement of at least a partial response or a metabolic response to most recent salvage therapy

No primary induction failure, defined as disease progression during or within 2 months after completion of first-line therapy

PATIENT CHARACTERISTICS:

Age

18 and over

Performance status

ECOG 0-1

Life expectancy

Not specified

Hematopoietic

Absolute neutrophil count ≥ 1,000/mm^3
Platelet count ≥ 75,000/mm^3

Hepatic

Bilirubin ≤ 2.0 mg/dL* NOTE: *Unless due to lymphoma or Gilbert's syndrome

Renal

Creatinine ≤ 2.0 mg/dL

Cardiovascular

Ejection fraction ≥ 45% by echocardiogram or MUGA

Pulmonary

DLCO ≥ 50% of predicted (corrected for alveolar volume)

Immunologic

No known HIV positivity
No active infection requiring oral or IV antibiotics
No autoimmune or other disease requiring long-term systemic steroids or other long-term immunosuppressants

Other

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Able to tolerate high-dose therapy
No other malignancy within the past 3 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

No prior bone marrow transplantation

Endocrine therapy

Not specified

Radiotherapy

Concurrent radiotherapy for disease progression after high-dose cyclophosphamide allowed at the discretion of the principal investigator

Surgery

Not specified
Intervention: Teriflunomide
Trial phase: Phase 3
ATC code: L04AA31
SMILES: C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 368
Group description: Teriflunomide 7 mg once daily for 108 weeks
Eligibility criteria:
Inclusion Criteria:

Multiple sclerosis [MS] subject who was ambulatory (EDSS of ≤ 5.5)
Exhibiting a relapsing clinical course, with or without progression (relapsing remitting, secondary progressive or progressive relapsing);
Meeting McDonald's criteria for MS diagnosis;
Experienced at least 1 relapse over the 1 year preceding the trial or at least 2 relapses over the 2 years preceding the trial;
No relapse onset in the preceding 60 days prior to randomization;
Clinically stable during the 30 days prior to randomization, without adrenocorticotrophic hormone [ACTH] or systemic steroid treatment.

Exclusion Criteria:

Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease;
Significantly impaired bone marrow function;
Pregnant or nursing woman;
Alcohol or drug abuse;
Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;
Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study;
Intervention: Teriflunomide
Trial phase: Phase 3
ATC code: L04AA31
SMILES: C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 358
Group description: Teriflunomide 14 mg once daily for 108 weeks
Eligibility criteria:
Inclusion Criteria:

Multiple sclerosis [MS] subject who was ambulatory (EDSS of ≤ 5.5)
Exhibiting a relapsing clinical course, with or without progression (relapsing remitting, secondary progressive or progressive relapsing);
Meeting McDonald's criteria for MS diagnosis;
Experienced at least 1 relapse over the 1 year preceding the trial or at least 2 relapses over the 2 years preceding the trial;
No relapse onset in the preceding 60 days prior to randomization;
Clinically stable during the 30 days prior to randomization, without adrenocorticotrophic hormone [ACTH] or systemic steroid treatment.

Exclusion Criteria:

Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease;
Significantly impaired bone marrow function;
Pregnant or nursing woman;
Alcohol or drug abuse;
Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment;
Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study;
Intervention: Anastrozole
Trial phase: Phase 2
ATC code: L02BG03
SMILES: CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: anastrozole

anastrozole: 1 mg QD
Eligibility criteria:
Inclusion Criteria:

Men ages 60 and older
Serum testosterone between 150-300 ng/dL
Symptoms suggestive of androgen deficiency
Intervention: Anastrozole
Trial phase: Phase 2
ATC code: L02BG03
SMILES: CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 35
Group description: placebo

anastrozole: 1 mg QD
Eligibility criteria:
Inclusion Criteria:

Men ages 60 and older
Serum testosterone between 150-300 ng/dL
Symptoms suggestive of androgen deficiency